For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...

Total product sales -- $7.3 billion in fiscal Q3 2025, up 4% sequentially from Q2 2025, with growth driven by the HIV ...

Gilead stock slumped late Thursday on soft product sales and lighter-than-expected revenue from its newcomer HIV prevention ...

People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...

Dzidzai is one of 25 Community Adolescent Treatment Supporters (CATS) trained by the National Aids Council (NAC) and the ...

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

More than 230 people became infected with HIV in Indiana, worsened by delayed action from former Gov. Mike Pence. Experts and ...

More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...

Researchers used cryo-EM to study how the HIV enzyme integrase arranges in 3D to slip its DNA into the host genome and pack ...

"You know, it's not the best news. But there was other news that could have been a lot worse, you know?" Charlie Sheen said.

UN World Children's Day on Nov 20 is an annual reminder that every child deserves the chance not just to survive, but to ...